Immunotherapy of AML: future directions.
Immunotherapy in the form of allogeneic GvL has been curing AML patients for nearly 30 years but our understanding of the mechanisms has been poor. Our rapidly evolving understanding of the human immune system and the concomitant technical developments in ex vivo cell manipulation, the vision of funding bodies, the dedication of clinical and research staff, and above all the commitment of our patients, promise substantial progress in the treatment of this disease in the year 2000 and beyond.
Lowdell
M W
MW
Department of Haematology, Royal Free and University College Medical School (RF Campus), London, UK. heg@rfhsm.ac.uk
Koh
M B
MB
D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D007951:Leukemia, Myeloid / Q000276:immunology / Q000601:surgery / Q000628:therapy*